MIB-1 Expression in breast carcinomas with medullary features. An immunohistological study including correlations with p53 and bcl-2

Virchows Archiv

Volumn 431, Issue 2, 1997, Pages 125-130

  Jensen, Vibeke ^a   Jensen, Marianne Lidang ^a   Kiær, Henrik ^c   Andersen, Jørn ^b   Melsen, Flemming ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

^c SVENDBORG HOSPITAL   (Denmark)

Author keywords

bcl 2; MIB 1; p53; Proliferative activity; Typical medullary carcinoma

Indexed keywords

KI 67 ANTIGEN; MONOCLONAL ANTIBODY KI 67; PROTEIN BCL 2; PROTEIN P53;

APOPTOSIS; ARTICLE; BREAST CARCINOMA; CELL PROLIFERATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MEDULLARY CARCINOMA; MICROWAVE IRRADIATION; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, NUCLEAR; BIOLOGICAL MARKERS; BREAST NEOPLASMS; CARCINOMA, MEDULLARY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MENOPAUSE; MIDDLE AGED; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030801997     PISSN: 09456317     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004280050078     Document Type: Article

References (46)

1. Barbareschi M, Leonardi E, Mauri FA, Serio G, Palma PD (1992) p53 and c-erb-2 protein expression in breast carcinomas. Am J Clin Pathol 98:408-418
2. Bertorelle R, Esposito G, Belluco C, Bonaldi L, Del Mistro A, Nitti D, Lise M, Chieco-Bianchi L (1996) p53 gene alterations and protein accumulation in colorectal cancer. J Clin Pathol [Mol Pathol] 49:M85-M90
3. Bosari S, Lee AKC, Viale G, Heatley GJ, Coggi G (1992) Abnormal p53 immunoreactivity and prognosis in node-negative breast carcinomas with long term follow-up. Virchows Arch [A] 421:291-295
4. Bouzubar N, Walker KJ, Griffith K, Ellis LO, Elston CW, Robertson JFR, Blamey RW, Nicholson RI (1989) Ki-67 immunostaining in primary breast cancer: pathological and clinical association. Br J Cancer 59:943-947
5. Cattoretti G, Becker MHG, Key G, Duchrow M, Schluter C, Galle J, Gerdes J (1992) Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol (Lond) 168:357-363
6. Cook DL, Weaver DL (1995) Comparison of DNA content, S-phase fraction, and survival between medullary and ductal carcinoma of the breast. Am J Clin Pathol 104:17-22
7. Davidoff AM, Herndon JE, Glover NS, Kerns BJM, Pence JC, Iglehart D, Marks JR (1991) Relation between p53 overexpression and established prognostic factors in breast cancer. Surgery 110:259-264
8. Diller L, Kassel J, Nelseon CE, Gryka MA, Litwak G, Gebhardt M, Bressac B, Ozturk M, Baker SJ, Vogelstein B, Freind SH (1990) p53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol 10:5772-5781
9. Domagala W, Harezga B, Szadowska A, Markiewski M, Weber K, Osborn M (1993) Nuclear p53 protein accumulates preferentially in medullary and high grade ductal but not rarely in lobular breast carcinomas. Am J Pathol 142:669-674
10. Drobnjak M, Latres E, Pollack D, Karpeh M, Dudas M, Woodruff JM, Brennan MF, Cordon-Cardo C (1994) Prognostic implication of p53 nuclear overexpression and high proliferation index soft tissue sarcomas. J Natl Cancer Inst 86:549-554
11. Friedrichs K, Gluba S, Eidtmann H, Jonat W (1993) Overexpression of p53 and prognosis in breast cancer. Cancer 72:3641-3647
12. Gerdes J, Schwab U, Lemke H, Stein H (1983) Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 31:13-20
13. Gerdes J, Lemke H, Baish H, Wacker HH, Schwab U, Stein H (1984) Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 4:1710-1715
14. Gerdes J, Stein H, Piliri S, Rivano MT, Gobbi M, Ralfkiaer E, Nielsen KM, Pallesen G, Bartels H, Palestro G, Delsol G (1987) Prognostic relevance of tumour-cell growth fraction in malignant non-Hodgkin's lymphomas. Lancet 11:448-449
15. Gorczyca W, Markiewski M, Kram A, Tuziak T, Domagala W (1995) Immunohistochemical analysis of bcl-2 and p53 expression in breast catcinomas: their correlation with Ki-67 growth fraction. Virchows Arch 426:229-233
16. Gundersen HJG, Østerby R (1981) Optimizing sampling efficiency of stereological studies in biology: or "Do more less well". J Microsc 121:65-73
17. Haldar S, Negrini M, Monne M, Sabbioni S, Croce CM (1994) Down regulation of bcl-2 by p53 in breast cancer cells. Cancer Res 54:2095-2097
18. Harn HJ, Ho LI, Liu CA, Liu GC, Lin FG, Lin JJ, Chang JY, Lee WH (1996) Down regulation of bcl-2 by p53 in nasopharyngeal carcinoma and lack of detection of its specific t(14;18) chromosomal translocation in fixed tissues. Histopathology 28:317-323
19. Harris CC, Hollstein M (1993) Clinical implications of the p53 tumor suppressor gene. N Engl J Med 329:1318-1327
20. Hockenbery D, Nunez G, Milliman C, Screiber RD, Korsmeyer SJ (1990) Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348:334-336
21. Hurlimann J (1993) Prognostic value of p53 protein in breast carcinomas. Pathol Res Pract 189:996-1003
22. Hurlimann J, Larrinaga B, Vala DLM (1995) bcl-2 protein in invasive ductal breast carcinomas. Virchows Arch 426:163-168
23. Jensen ML, Kiær H, Andersen J, Jensen V, Melsen F (1997) Prognostic comparison of three classifications for medullary carcinomas of the breast. Histopathology (in press)
24. Jensen V, Ladekarl M (1995) Immunhistochemical quantitation of oestrogen receptors and proliferative activity in oestrogen receptor positive breast cancer. J Clin Pathol 48:429-432
25. Jensen V, Ladekarl, Holm-Nielsen P, Melsen F, Sørensen FB (1995) The prognostic value of oncogenic antigen 519 (OA-519) expression and proliferative activity deteceted by antibody MIB-1 in node-negative breast cancer. J Pathol (Lond) 176:343-352
26. Joensuu H, Pylkkanen L, Toikkanen S (1994) Bcl-2 protein expression and long term survival in breast cancer. Am J Pathol 145:1191-1198
27. Keleti J, Quezado MM, Abaza MM, Raffeld M, Tsokos M (1996) The MDM2 oncoprotein is overexpressed in rhabdomyosarcoma cell lines and stabilizes wild-type p53 protein. Am J Pathol 149:143-151
28. Kerr JFR, Wyllie AH, Currie AR (1972) Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26:239-257
29. Keshgegian AA, Cnaan A (1995) Proliferation markers in breast carcinoma. Am J Clin Pathol 104:42-49
30. Levine AJ, Momand J, Finlay C (1991) The p53 tumour suppressor gene. Nature 352:453-436
31. Martinazzi M, Crivelli F, Zampatti C, Martinazzi S (1993) Relationship between p53 expression and other prognostic factors in human breast carcinoma. Am J Clin Pathol 100:213-217
32. Mercer WE, Sheilds MY, Amin M, Sauve GJ, Appella E, Romano JW, Ullrich SJ (1990) Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. Proc Natl Acad Sci USA 87:6166-6170
33. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B, Reed JC (1994) Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9:1799-1805
34. Ng IOL, Na J, Lai ECS, Fan ST, Ng M (1995) Ki-67 antigen expression in hepatocellular carcinoma using monoclonal antibody MIB-1. Am J Clin Pathol 104:313-318
35. Nigro J, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weston A, Modali R, Harris CC, Vogelstein B (1989) Mutations in the p53 gene occur in diverse human tumour types. Nature 342:705-708
36. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B (1992) Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358:80-83
37. Panchalingam S, Reynolds GM, Lammas DA, Rowlands DC, Kumararatne DS (1996) Simple method for pretreatment of tissue sections for the detection of apoptosis by in situ end-labelling and in situ nick translation. J Clin Pathol 49:M273-M277
38. Pezzella F, Morrison H, Jones M, Gatter KC, Lane D, Harris AL, Mason DY (1991) Immunohistochemical detection of p53 and bcl-2 proteins in non-Hodgkin's lymphoma. Histopathology 22:19-44
39. Rapin V, Contesso G, Mouriesse H, Bertin F, Lacombe MJ, Piekarski JD, Travagali JP, Gadenne C, Friedman S (1988) Medullary breast carcinoma. A reevaluation of 95 cases of breast cancer with inflammatory stroma. Cancer 61:2503-2510
40. Ridolfi RL, Rosen PP, Port A, Kinne D, Miké V (1977) Medullary carcinoma of the breast. A clinicopathologic study with 10 year follow-up. Cancer 40:1365-1385
41. Thor AD, Moore DH II, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT, Marcus JN, Schwartz L, Chen LC, Mayall BH, Smith HS (1992) Accumulation of p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancer. J Natl Cancer Inst 84:845-855
42. Ueda T, Aozasa K, Tsujimoto M, Ohsawa M, Uchida A, Aoki Y, Ono K, Matsumoto K (1989) Prognostic significance of Ki-67 reactivity in soft tissue sarcomas. Cancer 63:1607-1611
43. Wargotz ES, Silverberg S (1988) Medullary carcinoma of the breast: A clinicopathologic study with appraisal of current diagnostic criteria. Hum Pathol 19:1340-1346
44. Weidner N, Moore DH, Vartanian R (1994) Correlation of Ki-67 antigen expression with mitotic figure index and tumor grade in breast carcinomas using the novel "paraffin"-reactive MIB-1 antibody. Hum Pathol 25:337-342
45. Wijsman JH, Jonker RR, Keijzer R, Van deVelde CJH, Cornelisse CJ (1993) A new method to detect apoptosis in paraffin sections; in situ end-labelling of fragmented DNA. J Histochem Cytochem 41:7-12
46. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M (1991) Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352:345-347